Clinician’s guide to genes associated with Rett-like phenotypes – Investigation of a Danish cohort and review of the literature

Bitten Schönewolf-Greulich1,2, Anne-Marie Bisgaard1, Rikke S Møller3,4, Morten Dunø5, Karen Brøndum-Nielsen5, Simran Kaur6, Nicole J Van Bergen6, Sebastian Lunke7, Stefanie Eggers7, Cathrine Jespersgaard2, John Christodoulou6*, Zeynep Tümer2*

1. Center for Rett Syndrome, Kennedy Center, Department of Paediatrics, Copenhagen University Hospital, Rigshospitalet, Glostrup, Denmark
2. Applied Human Molecular Genetics, Kennedy Center, Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, Glostrup, Denmark
3. Danish Epilepsy Centre, Dianalund, Denmark
4. Institute for Regional Health Services, University of Southern Denmark, Odense, Denmark
5. Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
6. Neurodevelopmental Genomics Research Group, Murdoch Children's Research Institute, Melbourne and Department of Paediatrics, Melbourne Medical School, University of Melbourne, Melbourne, Australia.
7. Translational Genomics Unit, Murdoch Childrens Research Institute, Parkville, VIC, Australia

* Co-last authors

The authors declare no conflict of interests.

Correspondence to:
Bitten Schönewolf-Greulich
Center for Rett Syndrome
Kennedy Center
Rigshospitalet
Gl. Landevej 7
2600 Glostrup
Copenhagen, Denmark
Tel.: (+45) 43260150
E-mail: bitten.schoenewolf-greulich.01@regionh.dk

Keywords:

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/cge.13153

This article is protected by copyright. All rights reserved.
Rett-like, atypical Rett, RTT, MECP2, CDKL5, FOXG1, KCNB1, SMC1A
Abstract

The differential diagnostics in Rett syndrome has evolved with the development of next generation sequencing based techniques and many patients have been diagnosed with other syndromes or variants in newly described genes where the associated phenotype(s) is yet to be fully explored. The term Rett-like refers to phenotypes with distinct overlapping features of Rett syndrome where the clinical criteria are not completely fulfilled. In this paper we have combined a review of Rett-like disorders with data from a Danish cohort of 35 patients with Rett-like phenotypes emphasizing the diagnostic overlap with Pitt-Hopkins syndrome, Cornelia de Lange syndrome with SMC1A variants, and epileptic encephalopathies for example due to STXBP1 variants. We also found a patient with a pathogenic variant in KCNB1, which has not previously been linked to a Rett-like phenotype. This study underlines the clinical and genetic heterogeneity of a Rett syndrome spectrum, and provides an overview of the Rett syndrome-related genes described to date, and hence serves as a guide for diagnosing patients with Rett-like phenotypes.
The neurodevelopmental disorder Rett syndrome (RTT) was first described in 1966 by Dr. Andreas Rett, who reported 22 girls with loss of speech and hand use, and who developed hand stereotypies\textsuperscript{1}. Apart from the classical/typical form (RTT) there are atypical forms of RTT (atypical RTT) with different clinical subgroups such as “preserved speech variant”\textsuperscript{2}, the “early seizure variant”\textsuperscript{3,4} and the “congenital variant”\textsuperscript{5}. Today, the term Rett-like is used when there is an overlapping phenotype with typical or atypical RTT, but in whom the clinical criteria are not fulfilled. There are to date no formal published consensus criteria for a Rett-like diagnosis, and thus this description can be given to any patient with different combinations of the distinct features of RTT.

The genetic causes of typical RTT, atypical RTT and Rett-like disorders have been intensely studied. Typical RTT patients almost exclusively have pathogenic \textit{MECP2} variants\textsuperscript{6}, while atypical RTT and Rett-like patients show genetic heterogeneity. The most common genes involved apart from \textit{MECP2} are: \textit{CDKL5}, in which variants cause the early onset seizure disorder\textsuperscript{7} and \textit{FOXG1}, which is responsible for the congenital RTT variant\textsuperscript{8}. Several additional new genes have been suggested to be associated with atypical RTT and a Rett-like disorder\textsuperscript{9-12}. These studies have also revealed previously unrecognized clinical similarities of Rett spectrum phenotypes with other neurodevelopmental disorders. One of the unexpected findings has been the identification of \textit{SMC1A} variants, which are traditionally linked to Cornelia de Lange syndrome, in Rett-like patients\textsuperscript{13}. Furthermore, several Rett-like patients have pathogenic variants in epileptic encephalopathy genes\textsuperscript{14}. From a clinical perspective these findings enable an improved comprehension of the genetic landscape of atypical RTT and Rett-like disorders, potentially transforming the primary clinical diagnosis to a genetic one. From a research perspective, the genetic landscape is yet to completely unfold, and some of the genes associated with these phenotypes may be linked through similar functional pathways.

In this study, we present a genetic review of a Rett-like spectrum (typical RTT, atypical RTT, Rett-like disorder) and our findings in a Danish Rett-like cohort, including association of the
epilepsy gene, \textit{KCNB1}, as a new Rett-like gene. The purpose of this review is to provide a guide for molecular diagnosis of patients with Rett-like phenotypes.

**RETT SYNDROME**

RTT is mainly seen in females and presents with only a few neurodevelopmental symptoms before the age of 6-18 months\textsuperscript{15}. A period of regression will then occur, and abilities especially related to hand function and speech can deteriorate or be lost altogether\textsuperscript{16}. Hand stereotypies are a main feature and the patients often have severely impaired functional use of their hands\textsuperscript{17}. Another distinct clinical feature often present which can help point to the diagnosis is the breathing abnormalities (including hyperventilation and/or breath holding episodes)\textsuperscript{18}. Patients all have intellectual disability (ID). Other features that often develop over time include progressive microcephaly\textsuperscript{19}, and epilepsy (occurring in approximately 68\% at a mean age of 4.7 years)\textsuperscript{20, 21}. Scoliosis is also very common\textsuperscript{16}. Facial dysmorphism is not distinct, but few have subtle dysmorphic facial features which do not enable a clinical diagnosis\textsuperscript{22}.

Today the international diagnostic criteria published in 2010\textsuperscript{23} are used to assist in establishing the clinical diagnosis of RTT (listed in Table 1). RTT patients should have four main criteria (partial or complete loss of purposeful hand movements, partial or complete loss of spoken language, a gait abnormality, and stereotypic hand movements); while a diagnosis of atypical RTT is suggested if the patient has two or more of the main in addition to five or more of the supportive criteria\textsuperscript{23}. Both forms are characterized by a period of developmental regression followed by recovery or stabilization. In addition, the presence of any of the following features exclude a diagnosis of typical or classic RTT: a brain injury, a neurometabolic disease or neurological infection, and abnormal psychomotor development with an onset before the age of 6 months\textsuperscript{23}.

"Insert table 1 about here"

**THE RETT SYNDROME GENES**

\textit{MECP2}, encoding methyl CpG binding protein 2, is the major gene related to RTT and there are over 4600 \textit{MECP2} variants (pathogenic, benign, or with unknown significance) described in the
literature. MECP2 variants mainly cause RTT (including classical/typical and variant/atypical RTT), but may rarely also be associated with non-syndromic neurodevelopmental disorders including autism.

Variants in CDKL5 (Cyclin-dependent kinase-like 5) have been reported in about 500 patients and the most notable clinical feature of patients with pathogenic mutations of this gene is early onset epilepsy. These patients have ID and progressive microcephaly. Stereotypic hand movements, respiratory impairment with breath holding and hyperventilation, and severely impaired speech, hand function and gait may also be observed. These features are suggestive of RTT, but normal development during the first 6 months is rare in these patients and they often have facial dysmorphic features. Traditionally, the term Hanefeld or early onset epilepsy variant of RTT has been used for this diagnosis, but recently the term CDKL5 disorder has been introduced and is considered a separate clinical disorder from RTT.

FOXG1 variants are less common (approximately 80 cases in total) and neurodevelopmental impairment is already observable in early infancy. As FOXG1 is located on chromosome 14, variants affect males as well as females. This condition has therefore been called the congenital variant of RTT, and recently the term FOXG1 syndrome has been introduced. These patients exhibit profound motor dysfunction, and stereotypic hand movements and abnormal breathing can be present. There is rarely any speech development and eye contact is poor. Epilepsy is common although the age of onset can vary substantially. They have progressive microcephaly and MRI of the brain reveals poor myelinization and/or corpus callosum hypoplasia or agenesis.

MANY GENES, MANY DISORDERS
Apart from these three genes, there are at least 28 OMIM morbid genes described in literature in which variants may cause gene disorders/syndromes with overlapping Rett-like phenotypes. Some of these genes are associated with well-known syndromes such as Pitt-Hopkins syndrome (TCF4, CNTNAP2, NRXN1), Cornelia de Lange syndrome (SMC1A), Phelan-McDermid syndrome (SHANK3), Kleefstra syndrome (EHMT1), Christianson type X-linked mental retardation syndrome (SLC9A6), Angelman syndrome (UBE3A), and so on.
and Glass syndrome (SATB2). In addition, a substantial number of genes are epileptic encephalopathy genes (STXBP1, SCN1A, SCN2A, SCN1B, GRIN2A, GRIN2B, HCN1, SLC6A1, KCNA2, EEF1A2 and KCNB1).

“Insert table 2 about here”

DANISH COHORT OF RTT, ATYPICAL RTT AND RETT-LIKE PHENOTYPES
In Denmark, patients with clinical features suggestive of RTT are referred to the National Danish Centre for Rett syndrome and currently, we have registered 146 living patients. All these patients were initially investigated for the three known RTT genes and the sequence variant distribution is: MECP2 – 99 cases, CDKL5 – 10 cases, and FOXL1 – 2 cases.

Among the patients, without deficiencies in one of these three genes (n=35), pathogenic sequence variants were identified in SCN2A (n=1), STXBP1 (n=2) and TCF4 (n=1); all genes previously linked to Rett-like phenotype (Table 2), using different technologies including single gene or whole exome sequencing, and a previously described epilepsy gene panel39. Notably, in one patient we identified a de novo variant in KCNB1, which was not previously linked to Rett syndrome spectrum. Patient 2 (STXBP1) and patient 3 (SCN2A) have previously been published40, 41 Table 1).

Remaining patients were investigated using an in-house gene panel which included the genes described in Table 2. Through this approach we identified two patients with variants within SMC1A (n=1) and SHANK3 (n=1) (Table 1). With these results pathogenic variants of a total of 23 different have been found in RTT/atypical RTT/Rett-like patients (Fig. 1).

The project was approved by the Danish regional ethics committee, the regional dataprotection agency and informed consent was obtained from all participating patients.

“Insert Fig. 1 about here”

This article is protected by copyright. All rights reserved.
CLINICAL OR GENETIC DIAGNOSIS?
The description of variants within several different genes in patients with overlapping phenotypes creates practical challenges with diagnosis in clinical practice. Next generation sequencing based methodologies (gene panels or whole exome/genome sequencing) have overcome some difficulties and diagnosis tends to move from a sole clinical to a genetic confirmation. However, understanding the clinical picture of different disorders is crucial for selection of the most relevant genes to be investigated and for assessing the clinical significance of genomic variants identified in these genes. In the following section we will compare different disorders and causative genes in comparison with RTT features (Table 2).

Pitt-Hopkins and Pitt-Hopkins like syndromes
Pitt-Hopkins syndrome was first described in 1978 in patients with distinct facial dysmorphism and overbreathing\textsuperscript{42}. Neurodevelopment and speech are severely impaired, and several patients have progressive microcephaly and seizures\textsuperscript{28, 43}. Gait is often ataxic. Fetal pads on fingers and toes, and stereotypic hand movements such as hand clapping are important features. \textit{TCF4} is the main causative gene for the classical Pitt-Hopkins phenotype\textsuperscript{44}; variants in this gene have also been reported in two patients with a Rett-like phenotype\textsuperscript{10, 12}. In the Danish cohort a single patient suspected of having RTT due to hyperventilation and hand stereotypies has a pathogenic \textit{TCF4} variant (Table 1).

Bi-allelic loss-of-function variants in \textit{CNTNAP2} or \textit{NRXN1} can also result in a Pitt-Hopkins like phenotype\textsuperscript{45}. These patients also have severe ID and in some regression or stagnation in development\textsuperscript{45, 46}. Other prominent symptoms include epileptic seizures, a speech deficit with loss of verbal skills, and hyperventilation; and some of the patients are described as being non-dysmorphic.\textsuperscript{46} Even though variants of these genes are not yet found in Rett-like patients, they should be included in the genomic analyses of this patient group due the phenotypic overlap.

Cornelia de Lange syndrome (CdLS)
CdLS is characterized by ID, a recognizable pattern of dysmorphic facial features (synophrys, thick arched eyebrows, long eye lashes and downslanting palpebral fissures), hirsuitism, short neck, and
possible presence of major malformations, such as limb defects\textsuperscript{47}. There are five known genes associated with CdLS. Mutations in \textit{SMC1A} are the second most common cause of CdLS, and commonly associated with seizures, but limb defects are rare\textsuperscript{47}. The phenotype associated with \textit{SMC1A} variants may in some include Rett-like features\textsuperscript{47, 48} (Fig. 2). They may have hand stereotypes, apnea, microcephaly, and some have a period of regression. \textit{SMC1A} variants have been described in several patients with a Rett-like disorder\textsuperscript{11, 49}, and we identified a single patient with atypical RTT in the Danish cohort (Fig. 1). The phenotypic spectrum of \textit{SMC1A} spans from CdLS to Rett-like phenotypes, and \textit{SMC1A} can now be considered as the fourth most common gene mutated in patients with a clinical Rett syndrome spectrum (Fig. 1).

\textit{“Insert Fig. 2 about here”}

\textbf{Phelan-McDermid syndrome and \textit{SHANK3}}

Phelan-McDermid syndrome patients have various degrees of ID and speech deficits, epilepsy, hypotonia, structural brain and/or renal abnormalities and prevalent dysmorphic features, including a pointed chin and dysplastic toenails\textsuperscript{50, 51}. The syndrome is caused by microdeletions encompassing \textit{SHANK3} at 22q13 or a pathogenic variant in this gene, which is also associated with autism\textsuperscript{52}. \textit{SHANK3} variants have been reported in two patients with RTT\textsuperscript{53} and a Rett-like phenotype\textsuperscript{12}, respectively. In the Danish cohort a \textit{SHANK3} variant was identified in a single patient, who fulfills some of the main criteria of RTT, but due to her normal gait, not categorized as typical RTT. On the other hand she has classical autistic behavior compatible with a \textit{SHANK3} variant\textsuperscript{52}.

\textbf{Christianson type X-linked mental retardation}

Christianson type X-linked mental retardation syndrome was first described in 1999 in a large family with males affected with profound ID, absence of speech and epilepsy\textsuperscript{54}. Since then, several patients with common features (such as ataxic gait, hyperkinetic movements, a happy demeanor and poor fine motor skills) have been reported\textsuperscript{55, 56}. Epilepsy is reported in approximately 80\% of cases,
and some have had a period of regression\textsuperscript{55,56}. Because of this combination of clinical features, the syndrome has been considered a differential diagnosis of Angelman syndrome\textsuperscript{47}. Christianson type X-linked mental retardation is caused by pathogenic variants in \textit{SLC9A6} and has also been identified in two Rett-like patients\textsuperscript{11,12}.

\textbf{SATB2 Associated syndrome (Glass syndrome)}

Pathogenic variants in \textit{SATB2} have been identified in patients with neurodevelopmental disability, speech deficits and nonspecific dysmorphic features, which together have been named as Glass syndrome or “\textit{SATB2} associated syndrome”. Many patients have cleft palate or dental anomalies, but seizures were not prominent and they do not exhibit neurodevelopmental regression\textsuperscript{58,59}. \textit{SATB2} variants have also been described in two patients with a Rett-like phenotype, both of whom had hand stereotypies, impaired hand function and ID, but had no period of regression or seizures\textsuperscript{37}. \textit{SATB2} associated syndrome should be considered when evaluating Rett-like patients, especially if they have oral anomalies.

\textbf{Kleefstra syndrome}

The key features of Kleefstra syndrome are ID, hypotonia, dysmorphic features and cardiac defects\textsuperscript{36,60}. However, some characteristic symptoms overlapping with RTT, such as speech loss and impaired walking, may be present\textsuperscript{61}. Additional nonspecific RTT features, including microcephaly, a sleep disorder and teeth grinding, have been described numerously\textsuperscript{60}. Some patients have stereotypic movements and respiratory abnormalities, but are different to those observed in RTT patients\textsuperscript{36,61}. Kleefstra syndrome is caused by 9q34.3 microdeletions including \textit{EHMT1} or sequence variants of this gene\textsuperscript{60}. \textit{EHMT1} variants have not yet been reported in patients with a Rett-like phenotype, but have great phenotypic overlap and has been linked to the Rett-like spectrum\textsuperscript{36}.

\textbf{Angelman syndrome (AS)}

AS and RTT have often been described as potential differential diagnoses of each other, because they both present with severe ID, microcephaly, speech deficits and abnormal hand movements\textsuperscript{36}. However, there are clinically identifiable differences between AS and RTT: AS patients have facial
dysmorphism and they do not have hand wringing, but hand flapping. The EEG is almost always abnormal and often with a classical AS pattern. AS can be caused by several genetic/epigenetic mechanisms, including variations in *UBE3A*, variants of which have not yet been reported in Rett syndrome patients.

**Epilepsy**

More than 500 genes have been associated with epilepsy, including genes causing encephalopathy, and pathogenic variants of several of the latter have also been described in patients with Rett-like features (Table 2, Fig. 1). In Fig. 3 we have compiled the age of onset of seizures for all the genes that have been associated with RTT or Rett-like clinical spectrum, as the type and age of onset of epilepsy can be an important indicator of which group of genes is likely to be causative. The epileptic encephalopathies may overlap with Rett-like phenotypes, especially where there is a period of regression with the onset of epilepsy, together with progressive microcephaly, and intellectual, speech and motor deficits. Epileptic encephalopathies are defined as conditions where the progressive disturbance in cerebral function is thought to be the result of the epileptiform abnormalities. However, in some of the so-called epileptic encephalopathies it is likely that the neurodevelopmental co-morbidities are primary, since neurodevelopmental abnormalities can occur before the onset of seizures, and in fact some patients never experience any seizures. This has been the case with *STXBP1* variants, for instance, where patients have moderate to severe ID, speech deficits, ataxia and tremor, epilepsy is described in 95% of cases with a median age of 6 weeks but ranging from 1 day to 12 years. Six patients with a Rett-like phenotype, including two Danish patients, have been found to have *STXBP1* variants.

Variants in *SCN1A*, *SCN2A* and *SCN8A* lead to early onset of seizures and variants in these genes have been described in single cases with Rett-like features. The development of epilepsy is variable in these cases, but in all of them a period of regression has followed the epileptic seizures. In addition, patients may have ataxia, encephalopathy, various degrees of ID and hand stereotypies, and so these genes should be considered in Rett-like patients with early onset epilepsy. The severity of epilepsy is variable in patients with *SCN1A*, and an *SCN1A* variant was found in one patient with a Rett-like phenotype. In the Danish cohort we identified a single patient with an
SCN2A variant. She was referred with the suspicion of RTT, but her clinical history was more suggestive of a primary epileptic encephalopathy disorder, since the regression was related to the onset of intractable epilepsy.

GRIN2A and GRIN2B are two genes which cause ID and childhood onset epilepsy. Variants in GRIN2A cause a clinical heterogeneous disorder, and have been reported in 20% of patients with Landau-Kleffner syndrome, continuous spike and waves during slow-wave sleep syndrome and electroclinically atypical rolandic epilepsy. GRIN2B is currently considered an epileptic encephalopathy gene, but variants have been reported in patients both with and without epilepsy. Evaluation of larger cohorts is needed to better define the phenotype associated with variants in this gene. Notably, variations in GRIN2A and GRIN2B have been reported in three Rett-like patients, all of whom had hand stereotypes, whereas the patient with a GRIN2B variant also had a breathing disturbance.

Variants of HCN1 and SLC6A1 have been reported only in few patients in epileptic encephalopathy cohorts, and EEF1A2 variants were detected in a few patients with ID, dysmorphic facial features epilepsy with a variable age of onset. Variants in these genes are described in single patients with a Rett-like phenotype, including stereotypic hand movements and breathing abnormalities as distinct features of RTT.

KCNA2 variants are phenotypically linked to infantile epilepsy and episodic ataxia, but also to hereditary spastic paraplegia. The only Rett-like phenotype patient with a KCNA2 variant had an onset of regression a few months before the onset of intractable epilepsy. She also had loss of hand skills, hand stereotypes, microcephaly and a speech deficit.

KCNB1 has previously been described as a gene related to epileptic encephalopathy and ID, and sequence variants have only been described in a few patients, one of whom had handwringing. KCNB1 variants have not previously been described in Rett-like patients, even though they may be associated with clinical features overlapping with those of RTT. In the Danish cohort we identified a single case with pathogenic KCNB1 variant. The patient displayed many RTT features, including neurodevelopmental regression, loss of hand function, hand stereotypes and a speech deficit, and the onset of cognitive and motor decline was prior to her seizures. We suggest that this finding warrants the inclusion of KCNB1 in the expanding group of Rett-like genes.
WDR45 and other genes

WDR45 variants were first linked to a neurodegenerative disorder with iron deposits, and have been reported in four patients with an initial diagnosis of RTT or a Rett-like disorder, mainly because of cognitive and motor decline and hand stereotypies. Patients with WDR45 variants can be interpreted as Rett-like in the early stages of development before the brain MRI scans displaying the iron deposits typical of WDR45 disorder become obvious. Variants of all the other genes listed in Fig. 1, except for WDR45, have been observed in only one or two patients, and these genes are described in more detail in the supplementary material.

CLINICAL SIGNATURES OF RETT-LIKE PHENOTYPES

In a cohort of 35 Danish patients with Rett-like features but without MECP2, CDKL5 or FOXG1 variants, six patients revealed pathogenic changes in five other genes (SMC1A, TCF4, SHANK3, STXBP1 and SCN2A), previously linked to a Rett-like phenotype. Furthermore, we identified a KCNB1 variant, expanding the range of “Rett spectrum genes.”

These findings, together with the published reports, underscore that RTT and Rett-like phenotypes represent a clinically heterogeneous group of disorders, which may be designated as being part of a Rett syndrome spectrum (Fig. 1). The underlying genetic defects are also quite heterogeneous, with pathogenic variants reported in a number of genes, but where variants of each gene are detected in only a few patients, as outlined above. However, a number of recurrences have been reported in a number of genes such as SMC1A, TCF4, SHANK3 and WDR45, as well as a group of epileptic encephalopathy genes, all of which should be considered in the molecular diagnosis of patients with Rett-like phenotypes.
Since the reports of Andreas Rett and Bengt Hagberg and international colleagues, who undertook thorough initial evaluations of patients with RTT, unique co-morbidities have been identified. These co-morbidities distinguish patients with RTT from those who have other neurodevelopmental disorders. Some of the recent genes associated with Rett-like phenotypes were detected through a genotype first approach as a consequence of large scale genetic screening technologies, but not based on the clinical phenotype of the patients. However, it is possible to describe co-morbidities when patients are extensively phenotyped and compared to an adequate cohort of cases with mutations in the same gene. Descriptions of genes in a specific group of patients with a single major clinical feature like epilepsy may not emphasize other features or co-morbidities. Therefore, the full spectrum of the clinical picture will only be revealed when larger cohorts of patients with pathogenic variants of the same gene are described. This can lead to the “lumper” and “splitter” conundrum, where, for instance, newly identified genes associated with a Rett-like phenotype and severe epilepsy may be perceived as primary epileptic encephalopathies, or may be perhaps cast as separate syndromes based on their spectrum of co-morbidities. This has been discussed especially with regards to STXBP1 variants that have been recurrently reported in Rett-like patients (Fig. 1). We also suggest a new “Rett-like gene”, namely KCNB1, where several patients harbouring mutations in this gene have handwringing and regression.

In the Danish cohort we found that using the clinical criteria described by Neul et al (2010), the diagnosis of RTT is often very clear and pinpoints to a phenotype associated with MECP2 variants with great accuracy. However, it can be argued if the atypical RTT criteria really apply to patients with variants in CDKL5 and FOXG1, since these patients often have early neurodevelopmental symptoms and/or early onset epilepsy. We find that when diagnosing Rett-like patients it is helpful to establish the age of onset of epilepsy as a pointer to the correct molecular diagnosis (Fig. 3). In the Danish cohort, a female patient was molecularly diagnosed, at the age 52 years old, with a CDKL5 variant by direct sequencing, which was performed because clinical examination and a thorough medical history revealed a period of severe epilepsy in early infancy. Thus, it should always be remembered that the phenotype may evolve with time. However, one must be cautious about applying hard and definite rules. For instance for FOXG1 the mean age of onset of seizures has been reported as 6.8 years, but seizures can occur as early as 6 months of age, and not all of the
patients have seizures (87%)\textsuperscript{34}. Thus, a variant in this gene may be considered if there are other features suggestive of a \textit{FOXG1} defect, regardless age of onset of seizures (Fig. 3).

When evaluating a patient who does not fulfill the clinical RTT criteria but has overlapping features, some key features should be taken into consideration in order to establish the diagnosis: psychomotor development should be carefully assessed for the first year of life to evaluate the age of onset of regression, and the age of onset of epilepsy. Furthermore, careful characterization of hand movements and breathing pattern are invaluable. Because of the clinical and genetic heterogeneity, the diagnostic approach for patients with a Rett-like phenotype is shifting to a genotype first approach using gene panels, whole exome or genome sequencing. Nevertheless the clinical evaluation with identification of distinct clinical features is still highly crucial to assess the validity of causation of the putative sequence variants. Furthermore, as more patients with variants in the same genes are identified, clinical subgroups can be outlined.

**PERSPECTIVES**

From a clinical perspective an overview of the genes involved in typical RTT, atypical RTT and Rett-like phenotypes enables a better understanding of the genetic landscape of the RTT spectrum. From a research perspective the genes associated with Rett-like phenotypes need to be elucidated further in order to gain a more complete understanding of the genetic and functional networks involved. Apart from the known genes, variants in a number of other genes with yet unknown functions have been found through screening of large Rett-like phenotype cohorts\textsuperscript{10, 12}. Some of these may represent new candidate genes and further investigations of future cohorts and functional studies are necessary to establish their potential role in this disease pathogenesis. Furthermore, elucidation of the functional pathways involved could pave the way for the development of future targeted therapies.

**Acknowledgements**

We thank the patients and their families for participating in the project. The research has been funded by “Dr. Louises Børnehospitals Fond” and “Fonden til Lægevidenskabens Fremme”.

This article is protected by copyright. All rights reserved.
Legends for figures:

Figure 1:
23 OMIM genes found in Rett-like phenotypes in literature (dark grey) and in the Danish database (light grey).

Figure 2:
Clinical spectrum of SMC1A spanning from Rett syndrome to Cornelia de Lange Syndrome.

Figure 3:
Average time for first epileptic seizure.* indicates that >5% of patients with variations in this gene have been reported without epilepsy.

Reference List


Phenotype spectrum

- Regression
- Stereotypic hand movements
- Loss of hand movements
- Gait abnormality
- Breathing disturbance

- ID
- Epilepsy
- Speech deficit
- Microcephaly
- Growth retardation
- Gastroesophageal reflux
- Sleep disturbance

- Synophrys
- Limb defects
- Congenital heart disease
- Renal malformations

RTT

SMC1A

CdLS

figure2.jpg
Exploring the genes in Rett-like phenotypes

- Seizures
- Hand Stereotypies
- Breathing abnormality
- Regression
- Severe intellectual disability
- Gait abnormality
- Speech Deficit

CDKL5
- FOXG1
- SMC1A
- SCN2A
- TCF4
- SLC6A1
- IQSEC2
- ST3GAL5

MECP2
- STXBP1
- SHANK3
- WDR45
- GRIN2B

Graphical abstract.jpg
Table 1: Summary of the clinical RTT features of the Danish Rett-like cases.

<table>
<thead>
<tr>
<th>Gene</th>
<th>STXBP1</th>
<th>STXBP1</th>
<th>SCN2A</th>
<th>KCNB1</th>
<th>TCF4</th>
<th>SHANK3</th>
<th>SMC1A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>female</td>
<td>female</td>
<td>female</td>
<td>female</td>
<td>female</td>
<td>female</td>
<td>female</td>
</tr>
<tr>
<td>Variation</td>
<td>c.1061G&gt;A</td>
<td>c.230T&gt;A</td>
<td>c.3955C&gt;T</td>
<td>c.946G&gt;A</td>
<td>c.1669dupC</td>
<td>c.2265+1G&gt;A</td>
<td>c.3576delA</td>
</tr>
<tr>
<td>Inheritance</td>
<td>de novo</td>
<td>de novo</td>
<td>de novo</td>
<td>de novo</td>
<td>de novo</td>
<td>de novo</td>
<td>de novo</td>
</tr>
<tr>
<td>Head size</td>
<td>microcephaly</td>
<td>normal</td>
<td>progressive microcephaly</td>
<td>normal</td>
<td>progressive microcephaly</td>
<td>normal</td>
<td>progressive microcephaly</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>from birth to 6 months</td>
<td>from 2 weeks to 3 months</td>
<td>from 17 months</td>
<td>From 2 years</td>
<td>from 2 1/2 years</td>
<td>no</td>
<td>from 2 1/2 years</td>
</tr>
<tr>
<td>Other features</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>dysmorphic features</td>
<td>infections</td>
</tr>
</tbody>
</table>

**Diagnostic criteria for Rett syndrome:**

**Required diagnostic Criteria**

<table>
<thead>
<tr>
<th>Age for a period of regression followed by recovery or stabilization</th>
<th>1 1/2 years</th>
<th>none</th>
<th>17 months</th>
<th>6 months</th>
<th>none</th>
<th>5 1/2 years old</th>
<th>2 1/2 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria for typical RTT</td>
<td>0/3</td>
<td>1/3</td>
<td>0/3</td>
<td>0/3</td>
<td>0/3</td>
<td>0/3</td>
<td>0/3</td>
</tr>
<tr>
<td>Brain injury</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>Neurometabolic disease, or severe infection</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>Grossly abnormal development first 6 months</td>
<td>no</td>
<td>yes</td>
<td>no</td>
<td>no</td>
<td>yes</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>Hand skills</td>
<td>partial loss</td>
<td>impaired</td>
<td>poor</td>
<td>lost</td>
<td>poor</td>
<td>partial loss</td>
<td>partial loss</td>
</tr>
<tr>
<td>Language</td>
<td>lost</td>
<td>never acquired</td>
<td>never acquired</td>
<td>never acquired</td>
<td>never acquired</td>
<td>partial loss</td>
<td>lost</td>
</tr>
<tr>
<td>Gait</td>
<td>partial loss</td>
<td>impaired</td>
<td>impaired</td>
<td>no gait</td>
<td>impaired</td>
<td>normal</td>
<td>no gait</td>
</tr>
<tr>
<td>Stereotypic hand movements</td>
<td>no</td>
<td>no</td>
<td>Stereotypes or automatisms</td>
<td>hand wringing</td>
<td>hand wringing</td>
<td>hands to mouth</td>
<td>hand wringing</td>
</tr>
<tr>
<td>Breathing abnormality</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
</tr>
<tr>
<td>Bruxism</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>Impaired sleep pattern</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>Abnormal muscle tone</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
</tr>
<tr>
<td>Peripheral vasomotor disturbances</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>Scoliosis/kyphosis</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Growth retardation</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>yes</td>
</tr>
<tr>
<td>Small cold hands and feet</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Inappropriate laughing/screaming spells</td>
<td>no</td>
<td>no</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>Diminished response to pain</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>no</td>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>Intense eye communication</td>
<td>no</td>
<td>yes</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
</tr>
</tbody>
</table>

**RTT Diagnosis (based on the Neul criteria)**

<table>
<thead>
<tr>
<th>Atypical</th>
<th>Atypical</th>
<th>Atypical</th>
<th>Typical</th>
<th>RTT-like</th>
<th>RTT-like</th>
<th>Typical</th>
</tr>
</thead>
</table>

The HPO terms corresponding to the symptoms, which are part of the Rett-syndrome diagnostic criteria are listed in Supplementary table.
Table 2. List of causative genes in Rett-like diagnoses or differential diagnoses and the phenotypical overlap with Rett syndrome.

<table>
<thead>
<tr>
<th>Genes of polygeny</th>
<th>Genes of isolation</th>
<th>Developmental delay</th>
<th>Mental retardation</th>
<th>Sleep disturbance</th>
<th>Speech disorder</th>
<th>Seizures</th>
<th>Tardive movements</th>
<th>Epilepsy</th>
<th>Microcephaly</th>
<th>Macrocephaly</th>
<th>Sleep disturbance</th>
<th>Other common symptoms</th>
<th>Disorders</th>
<th>OMIM</th>
<th>Inheritance</th>
</tr>
</thead>
<tbody>
<tr>
<td>MECR2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rett Syndrome</td>
<td>312750</td>
<td>XLD</td>
</tr>
<tr>
<td>LCKLS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Epileptic encephalopathy 2</td>
<td>300672</td>
<td>XLD</td>
</tr>
<tr>
<td>FOXEI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rett syndrome, congenital variant</td>
<td>613454</td>
<td>AD</td>
</tr>
<tr>
<td>SNMLA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cornelia de Lange syndrome 2</td>
<td>300950</td>
<td>XLD</td>
</tr>
<tr>
<td>SEC4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pitt-Hopkins syndrome</td>
<td>610954</td>
<td>AD</td>
</tr>
<tr>
<td>CATMAPA2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pitt-Hopkins-like syndrome 1</td>
<td>610842</td>
<td>AR</td>
</tr>
<tr>
<td>MBD3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pitt-Hopkins-like syndrome 2</td>
<td>614325</td>
<td>AR</td>
</tr>
<tr>
<td>DNAH1K3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Phelan-McDermid syndrome</td>
<td>606232</td>
<td>AD</td>
</tr>
<tr>
<td>LA-TR2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CP</td>
<td>612313</td>
<td>AD</td>
</tr>
<tr>
<td>SUCCEAS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ataxia, mental retardation, X-linked syndromic, Christianon type</td>
<td>300243</td>
<td>XLD</td>
</tr>
<tr>
<td>SPMN12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CHD</td>
<td>610253</td>
<td>AD</td>
</tr>
<tr>
<td>LINCRA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Angelman syndrome</td>
<td>109380</td>
<td>AD</td>
</tr>
<tr>
<td>SCN2A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Epileptic encephalopathy 4</td>
<td>612164</td>
<td>AD</td>
</tr>
<tr>
<td>SCN2B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Epileptic encephalopathy, early infantile, 6 (Dravet syndrome)</td>
<td>607208</td>
<td>AD</td>
</tr>
<tr>
<td>SCN2D</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Epileptic encephalopathy, 11</td>
<td>613721</td>
<td>AD</td>
</tr>
<tr>
<td>SCN6B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Epileptic encephalopathy, 13</td>
<td>609702</td>
<td>AD</td>
</tr>
<tr>
<td>GANNA2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fragile X syndrome (Lundborg-Knudsen syndrome)</td>
<td>246530</td>
<td>AD</td>
</tr>
<tr>
<td>GANZ2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Epileptic encephalopathy, early infantile, 27</td>
<td>616139</td>
<td>AD</td>
</tr>
<tr>
<td>HCN1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Epileptic encephalopathy, early infantile, 24</td>
<td>607380</td>
<td>AD</td>
</tr>
<tr>
<td>LGNX2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Epileptic encephalopathy, early infantile, 25</td>
<td>616421</td>
<td>AD</td>
</tr>
<tr>
<td>KCNQ2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Epileptic encephalopathy, early infantile, 32</td>
<td>616366</td>
<td>AD</td>
</tr>
<tr>
<td>EEF1A2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Epileptic encephalopathy, early infantile 33</td>
<td>616409</td>
<td>AD</td>
</tr>
<tr>
<td>KCNB1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Epileptic encephalopathy, early infantile, 26</td>
<td>616056</td>
<td>AD</td>
</tr>
<tr>
<td>KCSN2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Neurodegeneration with brain iron accumulation 5</td>
<td>3008954</td>
<td>XLD</td>
</tr>
<tr>
<td>STINGAS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Spinal muscular atrophy, autosomal dominant 2</td>
<td>604086</td>
<td>AR</td>
</tr>
<tr>
<td>IQSEC2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X-linked mental retardation, MRX1</td>
<td>309530</td>
<td>XLD</td>
</tr>
<tr>
<td>MF21FC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MF21C haploinsufficiency syndrome</td>
<td>613443</td>
<td>AD</td>
</tr>
<tr>
<td>SUCLA2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Congenital disorder of glycosylation type Ia</td>
<td>300816</td>
<td>XLD</td>
</tr>
<tr>
<td>MPDIB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Congenital disorder of glycosylation type Ib</td>
<td>300817</td>
<td>XLD</td>
</tr>
<tr>
<td>GFR2Z8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ceroid lipofuscinosis neuronal 7</td>
<td>610951</td>
<td>AR</td>
</tr>
<tr>
<td>ZNF138</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Leukoencephalopathy with vanishing white matter</td>
<td>603895</td>
<td>AR</td>
</tr>
</tbody>
</table>

*(+ is noted if the symptom has been described in one or more patients with pathogenic variant in the gene).*

The symptoms emphasized are the main clinical features according to the 2010 classification of clinical Rett and other very specific features of Rett.

- ADHD: attention-deficit/hyperactivity disorder
- CHD: congenital heart disease
- MP: retinitis pigmentosa
- DP: deafness or hearing loss
- VL: visual loss
- FSD: epilepsy, focal, with speech disorder and with or without mental retardation

Grey colour are clinical symptoms in common with Rett.

list of causative genes.eps